[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642679":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":7,"responsibleParty":19,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":32,"maxAge":7,"enrollmentInfo":33,"targetDuration":7,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":7,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",null,[9,15],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Laetitia IMBERT, PhD","CONTACT","0383157879","+33","l.imbert@chru-nancy.fr",{"name":16,"role":11,"phone":17,"phoneExt":13,"email":18},"Veronique Roch, MSc","0383154276","v.roch@chru-nancy.fr",{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","IMBERT Laetitia","Prinicipal Investigator","100642679","prognostic-value-of-177lutetium-psma-single-photon-emission-tomography-and-timing-of-response-100642679",false,"NCT07643935","Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response","Prognostic Value of [¹⁷⁷Lu]Lu-PSMA SPECT and Timing of RECIP Assessment in mCRPC","RECIP","Inclusion Criteria:\n\n* Patients with metastatic castration-resistant cancer who received at least two cycles of 177Lu-PSMA\n\nExclusion Criteria:\n\n* Patients who refused to have their data used for research purposes","ALL","18 Years",{"count":34,"type":35},280,"ESTIMATED","OBSERVATIONAL","177Lutetium-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Early response assessment is critical for optimizing patient management. Response Evaluation Criteria in Prostate Imaging (RECIP) 1.0, initially developed for Positon Emission Tomography (PET) with 68Ga-PSMA, have demonstrated prognostic value, particularly after two treatment cycles. Recent studies suggest that SPECT at cycle 2 provides prognostic information, although it reflects only the first treatment cycle, whereas PET-based RECIP, assessed after cycle 2, captures the effect of two cycles. This study aims to evaluate the prognostic value of quantitative 177Lu-PSMA-SPECT biomarkers and determine the optimal timing for RECIP-based assessment.",[39],"Therapy-Associated Cancer","NOT_YET_RECRUITING","2026-06-10",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":35},"2026-07-01",{"date":48,"type":35},"2026-12-01",{"name":5,"class":6}]